Abstract
Methods 60 subjects (18–50 yrs) were randomized to 6 schedules. Group 1 (n = 30) received 3 DNA prime vaccinations (Wks 0,4,8) and Group 2 (n = 30) received a recombinant adenoviral vector (rAd5) prime vaccination (Wk 0). Both groups received rAd5 booster at Wk 24. Subjects were equally randomized to receive prime injections by IM, SC and ID routes. DNA dosage was 4 mg for IM and SC; 0.4 mg for ID injections. rAd5 dosage was 1010 PU by all routes. Half of the subjects in each group had pre-existing Ad5 neutralizing antibody.
Highlights
AIDS Vaccine 2009 Anna Laura Ross Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf
Safety and tolerability of the VRC/NIAID DNA and rAd5 HIV-1 vaccines administered by intramuscular (IM), subcutaneous (SC), and intradermal (ID) routes of administration were evaluated in VRC 011
Local reactions for ID and SC injections had different characteristics compared to the IM injections, which have typically been used for these vaccines in prior phase I/II studies
Summary
Safety and tolerability of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular, subcutaneous and intradermal administration in healthy adults. ME Enama*1, L Novik, L Holman, I Gordon, M Nason, J Ledgerwood and BS Graham. Address: 1VRC/NIAID/NIH, Bethesda, MD, USA and 2BRB/NIAID/NIH, Bethesda, MD, USA * Corresponding author from AIDS Vaccine 2009 Paris, France. Published: 22 October 2009 Retrovirology 2009, 6(Suppl 3):P200 doi:10.1186/1742-4690-6-S3-P200. AIDS Vaccine 2009 Anna Laura Ross Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
